Lantheus Holdings (LNTH) Stock Analysis & AI Equity Report

Drug Manufacturers - Specialty & Generic USD Explore free reports

Lantheus Holdings (LNTH) overview

Lantheus Holdings (LNTH) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 1,542m and operating profit of USD 311m; the year-end share price was 66.55 USD and market capitalisation was USD 4,298m. Lantheus Holdings is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Lantheus Holdings's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 1,090mFY 2025
Share price66.55 USDFY 2025 year end
RevenueUSD 1,542mFY 2025
Operating profitUSD 311mFY 2025
Net earningsUSD 234mFY 2025
Market capitalisationUSD 4,298mFY 2025 year end

About Lantheus Holdings

Lantheus develops and markets radiopharmaceutical products and related solutions used by healthcare professionals to detect, characterize, or rule out disease. Its offerings include radiopharmaceutical oncology products, precision diagnostics, biomarkers, digital solutions and contract development and manufacturing services. The company sells primarily to hospitals, independent imaging centers and government facilities, and serves clinicians across multiple specialties and settings.

Generate the Lantheus Holdings report

Lantheus Holdings is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Lantheus Holdings and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Lantheus Holdings

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.